Home LiteratureArticle Details
PMID: 23685212 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain.

Structure (London, England : 1993) ·Vol. 21 ·No. 6 ·2013-06-04 ·Pages 1042-50

Bohn MF, Shandilya SM, Albin JS, Kouno T, Anderson BD, McDougle RM, Carpenter MA, Rathore A, Evans L, Davis AN, Zhang J, Lu Y, Somasundaran M, Matsuo H, Harris RS, Schiffer CA

Abstract

Human APOBEC3F is an antiretroviral single-strand DNA cytosine deaminase, susceptible to degradation by the HIV-1 protein Vif. In this study the crystal structure of the HIV Vif binding, catalytically active, C-terminal domain of APOBEC3F (A3F-CTD) was determined. The A3F-CTD shares structural motifs with portions of APOBEC3G-CTD, APOBEC3C, and APOBEC2. Residues identified to be critical for Vif-dependent degradation of APOBEC3F all fit within a predominantly negatively charged contiguous region on the surface of A3F-CTD. Specific sequence motifs, previously shown to play a role in Vif susceptibility and virion encapsidation, are conserved across APOBEC3s and between APOBEC3s and HIV-1 Vif. In this structure these motifs pack against each other at intermolecular interfaces, providing potential insights both into APOBEC3 oligomerization and Vif interactions.

MeSH Terms
Catalysis Crystallography, X-Ray Cytosine Deaminase/chemistry,metabolism HIV-1/metabolism Models, Molecular Protein Conformation vif Gene Products, Human Immunodeficiency Virus/metabolism
Chemicals
vif Gene Products, Human Immunodeficiency Virus vif protein, Human immunodeficiency virus 1 APOBEC3F protein, human Cytosine Deaminase
Authors & Affiliations
16 authors, click to expand affiliations / ORCID
Bohn Markus-Frederik
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Shandilya Shivender M D
Albin John S
Kouno Takahide
Anderson Brett D
McDougle Rebecca M
Carpenter Michael A
Rathore Anurag
Evans Leah
Davis Ahkillah N
Zhang Jingying
Lu Yongjian
Somasundaran Mohan
Matsuo Hiroshi
Harris Reuben S
Schiffer Celia A
References (63)
63 references, click to expand
  1. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    Nature. 2002 Aug 8;418(6898):646-50 PMID: 12167863
  2. DNA deamination mediates innate immunity to retroviral infection.
    Cell. 2003 Jun 13;113(6):803-9 PMID: 12809610
  3. Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity.
    J Virol. 2010 Aug;84(16):8193-201 PMID: 20519393
  4. Creative deaminases, self-inflicted damage, and genome evolution.
    Ann N Y Acad Sci. 2012 Sep;1267:79-85 PMID: 22954220
  5. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
    Expert Rev Mol Med. 2010 Jan 22;12:e4 PMID: 20096141
  6. Functional domain organization of human APOBEC3G.
    Virology. 2008 Sep 15;379(1):118-24 PMID: 18639915
  7. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Curr Biol. 2004 Aug 10;14(15):1385-91 PMID: 15296757
  8. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.
    Annu Rev Immunol. 2008;26:317-53 PMID: 18304004
  9. APOBEC3B is an enzymatic source of mutation in breast cancer.
    Nature. 2013 Feb 21;494(7437):366-70 PMID: 23389445
  10. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Curr Biol. 2005 Jan 26;15(2):166-70 PMID: 15668174
  11. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif.
    J Biol Chem. 2010 Dec 24;285(52):40785-92 PMID: 20971849
  12. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.
    J Virol. 2007 Apr;81(8):3807-15 PMID: 17267497
  13. An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model.
    J Mol Biol. 2009 Jun 26;389(5):819-32 PMID: 19389408
  14. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.
    J Biol Chem. 2003 Feb 21;278(8):6596-602 PMID: 12480936
  15. APOBEC-mediated viral restriction: not simply editing?
    Trends Biochem Sci. 2007 Mar;32(3):118-28 PMID: 17303427
  16. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity.
    Proteins. 2007 Nov 1;69(2):270-84 PMID: 17598142
  17. Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif.
    J Virol. 2010 Dec;84(24):12599-608 PMID: 20943965
  18. Mutational processes molding the genomes of 21 breast cancers.
    Cell. 2012 May 25;149(5):979-93 PMID: 22608084
  19. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain.
    Cell. 2011 Apr 29;145(3):423-34 PMID: 21496894
  20. The restriction factors of human immunodeficiency virus.
    J Biol Chem. 2012 Nov 30;287(49):40875-83 PMID: 23043100
  21. Guidelines for naming nonprimate APOBEC3 genes and proteins.
    J Virol. 2009 Jan;83(2):494-7 PMID: 18987154
  22. A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase.
    J Biol Chem. 2009 Aug 21;284(34):22898-904 PMID: 19561087
  23. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions.
    Mol Cell. 2012 May 25;46(4):424-35 PMID: 22607975
  24. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.
    EMBO J. 2004 Jun 16;23(12):2451-8 PMID: 15152192
  25. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators.
    Mol Cell. 2002 Nov;10(5):1247-53 PMID: 12453430
  26. Determinants of sequence-specificity within human AID and APOBEC3G.
    DNA Repair (Amst). 2010 May 4;9(5):579-87 PMID: 20338830
  27. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G.
    Nature. 2008 Mar 6;452(7183):116-9 PMID: 18288108
  28. The APOBEC-2 crystal structure and functional implications for the deaminase AID.
    Nature. 2007 Jan 25;445(7126):447-51 PMID: 17187054
  29. APOBEC3G & HTLV-1: inhibition without deamination.
    Retrovirology. 2005 May 29;2:37 PMID: 15921532
  30. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Nature. 2003 Jul 3;424(6944):94-8 PMID: 12808465
  31. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.
    J Virol. 2008 Mar;82(6):2652-60 PMID: 18184715
  32. Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID.
    J Exp Med. 2010 Jan 18;207(1):141-53 PMID: 20048284
  33. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection.
    Nature. 2011 Dec 21;481(7381):371-5 PMID: 22190037
  34. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent.
    Virology. 2009 May 10;387(2):313-21 PMID: 19304304
  35. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.
    J Virol. 2007 Dec;81(24):13346-53 PMID: 17928335
  36. Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction.
    J Biol Chem. 2012 May 11;287(20):16965-74 PMID: 22451677
  37. Cytidine deamination of retroviral DNA by diverse APOBEC proteins.
    Curr Biol. 2004 Aug 10;14(15):1392-6 PMID: 15296758
  38. Mutational analysis of the human immunodeficiency virus type 1 Vif protein.
    J Virol. 1999 Apr;73(4):2675-81 PMID: 10074113
  39. Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
    J Biol Chem. 2007 Jan 19;282(3):1585-94 PMID: 17142455
  40. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
    J Virol. 2010 Oct;84(19):10209-19 PMID: 20686027
  41. Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G.
    EMBO J. 2009 Feb 18;28(4):440-51 PMID: 19153609
  42. Diverse functions for DNA and RNA editing in the immune system.
    RNA Biol. 2010 Mar-Apr;7(2):220-8 PMID: 20220309
  43. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals.
    BMC Mol Biol. 2008 Nov 18;9:104 PMID: 19017397
  44. APOBEC3 proteins mediate the clearance of foreign DNA from human cells.
    Nat Struct Mol Biol. 2010 Feb;17(2):222-9 PMID: 20062055
  45. Innate immunity in resistance to HIV infection.
    J Infect Dis. 2010 Nov 1;202 Suppl 3:S361-5 PMID: 20887225
  46. Hypermutation of HIV-1 DNA in the absence of the Vif protein.
    Science. 2003 May 16;300(5622):1112 PMID: 12750511
  47. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications.
    Nature. 2008 Nov 6;456(7218):121-4 PMID: 18849968
  48. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G.
    ACS Chem Biol. 2012 Mar 16;7(3):506-17 PMID: 22181350
  49. Structural disorder in the HIV-1 Vif protein and interaction-dependent gain of structure.
    Protein Pept Lett. 2010 Aug;17(8):988-98 PMID: 20450485
  50. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
    J Biol Chem. 2007 Jan 26;282(4):2587-95 PMID: 17121840
  51. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
    Science. 2003 Nov 7;302(5647):1056-60 PMID: 14564014
  52. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
    Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 PMID: 9254694
  53. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces.
    Structure. 2010 Jan 13;18(1):28-38 PMID: 20152150
  54. The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state.
    Protein Eng Des Sel. 2009 May;22(5):281-7 PMID: 19218568
  55. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    PLoS Pathog. 2008 Jul 04;4(7):e1000095 PMID: 18604271
  56. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
    J Virol. 2004 Jun;78(11):6073-6 PMID: 15141007
  57. T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction.
    Nature. 2011 Dec 21;481(7381):376-9 PMID: 22190036
  58. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding.
    Nat Struct Mol Biol. 2012 Oct;19(10):1005-10 PMID: 23001005
  59. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation.
    J Exp Med. 2006 Apr 17;203(4):865-70 PMID: 16606671
  60. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.
    Virology. 2006 May 25;349(1):31-40 PMID: 16460778
  61. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Nature. 2003 Jul 3;424(6944):99-103 PMID: 12808466
  62. The AID/APOBEC family of nucleic acid mutators.
    Genome Biol. 2008;9(6):229 PMID: 18598372
  63. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
    J Virol. 2003 Nov;77(21):11398-407 PMID: 14557625
Article Info
Journal
Structure (London, England : 1993)
Abbr.
Structure
ISSN
1878-4186
DOI
10.1016/j.str.2013.04.010
Published
2013-06-04
Epub
2013-00-16
Pages
1042-50
Language
English
Region
United States
NLM ID
101087697
PMCID
PMC3805256
Subset
IM
Grants
NIAID NIH HHS · T32 AI083196 · United States
NIGMS NIH HHS · Y1 GM1104 · United States
NIH HHS · S10 OD012028 · United States
NCI NIH HHS · Y1 CO1020 · United States
NIGMS NIH HHS · P01 GM091743 · United States
NIGMS NIH HHS · R01 GM093833 · United States
External Links
PubMed source DOI: 10.1016/j.str.2013.04.010 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2